In response to: Heise T, Nørskov M, Nosek L, Kaplan K, Famulla S and Haahr H. L. (2017) Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared to insulin glargine U300 in type 1 diabetes. Diabetes Obes Metab. 2017;19:1032-1039

Diabetes Obes Metab. 2018 Aug;20(8):2043-2047. doi: 10.1111/dom.13308. Epub 2018 May 6.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Diabetes Mellitus, Type 1*
  • Humans
  • Hypoglycemic Agents
  • Insulin Glargine
  • Insulin, Long-Acting

Substances

  • Hypoglycemic Agents
  • Insulin, Long-Acting
  • Insulin Glargine
  • insulin degludec